JP2017511324A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511324A5
JP2017511324A5 JP2016559965A JP2016559965A JP2017511324A5 JP 2017511324 A5 JP2017511324 A5 JP 2017511324A5 JP 2016559965 A JP2016559965 A JP 2016559965A JP 2016559965 A JP2016559965 A JP 2016559965A JP 2017511324 A5 JP2017511324 A5 JP 2017511324A5
Authority
JP
Japan
Prior art keywords
adjuvant
composition
immunogenic composition
rts
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559965A
Other languages
English (en)
Japanese (ja)
Other versions
JP6645982B2 (ja
JP2017511324A (ja
Filing date
Publication date
Priority claimed from GBGB1405921.6A external-priority patent/GB201405921D0/en
Application filed filed Critical
Publication of JP2017511324A publication Critical patent/JP2017511324A/ja
Publication of JP2017511324A5 publication Critical patent/JP2017511324A5/ja
Application granted granted Critical
Publication of JP6645982B2 publication Critical patent/JP6645982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559965A 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法 Active JP6645982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
GB1405921.6 2014-04-02
PCT/EP2015/057424 WO2015150568A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (3)

Publication Number Publication Date
JP2017511324A JP2017511324A (ja) 2017-04-20
JP2017511324A5 true JP2017511324A5 (Direct) 2018-05-17
JP6645982B2 JP6645982B2 (ja) 2020-02-14

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016559965A Active JP6645982B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法
JP2016560336A Expired - Fee Related JP6655549B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016560336A Expired - Fee Related JP6655549B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法

Country Status (18)

Country Link
US (3) US10688168B2 (Direct)
EP (2) EP3125929B8 (Direct)
JP (2) JP6645982B2 (Direct)
KR (2) KR20160132115A (Direct)
CN (2) CN106456738B (Direct)
AR (1) AR099960A1 (Direct)
AU (1) AU2015239025B2 (Direct)
BE (1) BE1022355B1 (Direct)
BR (2) BR112016022463A2 (Direct)
CA (2) CA2943711A1 (Direct)
EA (1) EA037405B1 (Direct)
ES (2) ES2853773T3 (Direct)
GB (1) GB201405921D0 (Direct)
IL (1) IL247493B (Direct)
MX (3) MX2016012932A (Direct)
SG (1) SG11201607086QA (Direct)
WO (2) WO2015150568A1 (Direct)
ZA (1) ZA201605955B (Direct)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US12016919B2 (en) 2017-05-30 2024-06-25 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
RS52187B (sr) 2004-10-14 2012-10-31 Crucell Holland B.V. Vakcine za indukciju i stimulaciju imunskog odgovora za malariju
SI1877426T1 (sl) * 2005-04-29 2012-06-29 Glaxosmithkline Biolog Sa Postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2668100C (en) * 2006-11-01 2014-12-23 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
EP2998316B1 (en) * 2007-03-02 2019-06-12 GlaxoSmithKline Biologicals S.A. Novel method and compositions
US9452209B2 (en) * 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
DK2315834T3 (en) * 2008-07-25 2018-08-20 Glaxosmithkline Biologicals Sa Tuberculosis Rv2386c protein, compositions and uses thereof
JP5824360B2 (ja) * 2008-07-25 2015-11-25 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物および方法
HUE031044T2 (en) * 2008-07-25 2017-06-28 Glaxosmithkline Biologicals Sa Polypeptides, polynucleotides and compositions for use in the treatment of latent tuberculosis
WO2011092253A1 (en) * 2010-01-27 2011-08-04 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
CN103249431B (zh) * 2010-12-14 2016-11-02 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
WO2015126930A2 (en) * 2014-02-18 2015-08-27 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10004793B2 (en) * 2014-04-24 2018-06-26 Statens Serum Institut M.tuberculosis vaccines
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Similar Documents

Publication Publication Date Title
JP2017511324A5 (Direct)
Garçon et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Weeratna et al. CpG DNA induces stronger immune responses with less toxicity than other adjuvants
CN106163551B (zh) 单瓶疫苗制剂
Skene et al. Saponin-adjuvanted particulate vaccines for clinical use
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
JP2017511327A5 (Direct)
TW200722101A (en) Novel composition
Lowell et al. Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain
HRP20230359T1 (hr) Imunogeni pripravak
HUE031740T2 (en) A vaccine composition comprising a synthetic adjuvant
US11951161B2 (en) Methods for inducing an immune response
JP2018500322A5 (Direct)
JP2015520196A5 (Direct)
IL276661B2 (en) Immunogenic preparation containing staphylococcal antigens
JP2018532782A5 (Direct)
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
WO2024127215A3 (en) Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
Al Saleh et al. MicroCrystalline Tyrosine-adsorbed immunotherapy
Sisteré-Oró et al. Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
US10973900B2 (en) Dried composition
WO2022076723A8 (en) Imdq-peg-chol adjuvant and uses thereof
Kanchan et al. Role of alum in improving the immunogenicity of biodegradable polymer particle entrapped antigens
WO2021101187A3 (ko) 바바킨을 포함하는 신규 백신용 면역보조제 조성물
RU2020112504A (ru) Композиции и способы для вызывания иммунного ответа против clostridium difficile